RWE for 2nd MSB COVID-19 ARDS P3 Trial, page-233

Here is a SARS-CoV-2 study undertaken right here in Victoria that IMO further supports the need for the additional phase 3 COVID-19 ARDS trial using Remestemcel-L .... the 12 month data from the first phase 3 COVID-19 ARDS trial could also demonstrate whether patients treated with Remestemcel-L had better outcomes in these highlighted areas ?

If you look at the findings summary paragraph below one might also draw the conclusion (long bow I know) that there may be an increased demand for treatments like Rexlemestrocel-L in the future given the elevated risks for heart related problems associated with patients hospitalised with SARS-CoV-2 ?


Interesting study nonetheless if anyone wants to have a read as you can download the full 32 page paper for free at the end of the article.


https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4025054

Complications Following SARS-CoV-2 Infection in Victoria, Australia: A Record Linkage Study

31 Pages Posted: 3 Feb 2022

Abstract


Background: SARS-CoV-2 infection can induce significant pathologies including neurological, cardiac and vascular disease events. We assessed strength of association between SARS-CoV-2 infection and several key respiratory and non-respiratory complications in Victoria, Australia.


Methods: Record linkage was used to assemble all laboratory-confirmed COVID-19 cases notified 1 January 2020–31 May 2021 with corresponding hospitalisation episodes to 30 September 2021. Hospitalisation rates and reasons for hospitalisation among cases was assessed using a cohort study design. A self-controlled case series was used to assess strength of association between SARS-CoV-2 infection and several outcomes in the first 90 days following COVID-19 illness onset. Incident rate ratios (IRR) and 95% confidence intervals were calculated comparing risk in the post-exposure period with a baseline period prior to SARS-CoV-2 infection.


Findings: There were 20,594 COVID-19 cases, with 2,992 (14·53%) related hospitalisation s. In the 90-days following COVID-19 illness onset, elevated risks were observed for myocarditis and pericarditis (IRR: 14·76, 95% confidence interval 3·19–68·30); thrombocytopenia (IRR: 7·38, 4·36–12·50), pulmonary embolism (IRR: 6·37; 3·55–11·43), acute myocardial infarction (IRR: 3·89, 2·59–5·84) and cerebral infarction and non-ischemic stroke (IRR: 2·31, 1·37–3·90).


Interpretation: There is a strong association between SARS-CoV-2 infection and risk of several complications highlighting the value of COVID-19 pandemic mitigation measures such as vaccination. Improved awareness of these risks may support early diagnosis and management of patients with a past history of SARS-CoV-2 infection, and contribute to a greater understanding of the public health burden of COVID-19.


Funding Information: No funding was provided for this study.